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Background: Much research is being carried out to find a tumor marker for early diagnosis of 
breast cancer when the lesion is still small. CA15-3, a glycoprotein, is one candidate with probable 
use as tumor marker in breast cancer. 
Objective: We conducted this study to analyze the relationship between serum levels of CA15-
3 and several variables including age, clinical stage, and the number of lymph nodes involved in 
breast cancer patients. 
Methods: One hundred and thirty-six females including 39 normal controls, 54 patients with 
benign lesions, and 43 with malignant lesions entered this study. A second and third sample was 
obtained from patients who were diagnosed as having breast cancer, one week and one month 
postmastectomy, respectively. CA15-3 was measured by ELISA.  
Results: The number of patients in the malignant group (6 out of 43) with elevated CA15-3 
levels was higher than that in the normal controls (3 out of 39) and patients with benign lesions (1 
out of 54). Forty percent of patients in stages II and III had a higher frequency of abnormal CA15-3 
values, whereas 13% of those in stage I disease did so. One week after mastectomy, the mean ± SD 
serum CA15-3 was 18.3 ± 14.6 U/mL. However, a month later, the mean ± SD was 21.7±19.7 U/mL, 
which was approximately the same as the preoperative values (mean ± SD: 22.1 ± 25.6 U/mL). There 
was an abnormal elevation in CA15-3 values when ≥4 lymph nodes were involved. The correlation 
between the elevated CA15-3 values and the number of involved lymph nodes was significant (P < 
0.001).  Analysis of the CA15-3 values showed a sensitivity of 14.0% and a specificity of 92.3%. The 
positive and negative predictive values were 66.7% and 49.3%, respectively. The relative efficiency 
was 1.8%.  
Conclusion: In this study, CA15-3 was found to have no value in the screening for early 
diagnosis of breast cancer. We observed a strong correlation between elevated CA15-3 levels and 
the progression of breast cancer.  
 
Archives of Iranian Medicine, Volume 8, Number 4, 2005: 263 – 266. 
 
Keywords: Breast cancer • CA15-3  • prognosis  • tumor markers    
  
 
Introduction 
 
reast cancer is a well-known disease. 
Described by Egyptians, the reports of 
the disease date back to 3,000 B.C. A 
Persian physician, Democedes, is said to have 
cured the wife of the king Dariush. She suffered 
from a tumor in her breast, which was ulcerated 
and spread.1 
Unfortunately, even after 5,000 years, the death 
toll for breast cancer has remained stable. 
Therefore, much research is being done to 
diagnose the cancer early when the lesion is still 
small. If diagnosed at an early stage, a surgical 
procedure can totally remove the tumor and the 
patient will be completely cured. 
One area under intense research is a search for 
an ideal tumor marker. One of the features of an 
ideal tumor marker is being specific for that type 
of tumor. In other words, normal individuals or 
patients with benign lesions should not have 
detectable levels of that marker. The tumor marker 
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should also be sensitive enough to detect tumors, 
while they are still small, i.e., in the early stages of 
the disease as well as during recurrences. Finally, 
these markers must be readily accessible through 
sampling of body fluids.2 One group of tumor 
markers are the mucin-like glycoproteins, which 
are all defined by specific monoclonal antibodies 
(MAbs).  
We decided to work on the tumor marker 
CA15-3. This tumor marker is a breast cancer-
associated antigen, which is defined by two distinct 
MAbs. The antibodies bind DF3 and 115D8 
antigens. DF3 antigen is found on the surface of 
human mammary cancer cells, whereas 115D8 
antigen is found on the human milk fat globule 
membrane.3 Both antigens are eventually released 
into the surrounding fluids. No previous survey has 
been done on CA15-3 in Iran. Therefore, we 
decided to conduct this study to analyze the 
potential uses of CA15-3 in early diagnosis of 
breast cancer patients among the Iranians.  
 
Patients and Methods 
 
CA15-3 can be quantified with monoclonal 
antibodies, using two different methods. The 
antigen level can be determined using radioim-
munoassay based on a competitive binding 
principle or using a sandwich format with the 
ELISA method. Recently, ELISA has become the 
more popular method for evaluating the level of 
tumor marker in the serum. Nonetheless, the 
ELISA also has its drawbacks, known as the hook 
effect. This is observed in certain samples where 
the tumor marker level is high, but a falsely low 
value is read.4 
One hundred and thirty-six females were 
entered into this study. Five mL blood was 
collected from all females and transferred to the 
laboratory on ice. After the clotting, the blood 
samples were centrifuged. The serum was 
transferred to another tube and stored at -20ûC until 
use. CA15-3 was measured by ELISA (the Conc 
Ag Diagnostic kit) according to the manufac- 
turers instructions. Values ≥30 U/mL were 
considered abnormal.  
The patients in this survey were divided into 
three groups including 39 normal controls chosen 
from the laboratory personnel who showed no 
evidence of disease after a complete physical 
examination and laboratory work-up including a 
chest radiograph, liver function test, bone scan, 
mammography, etc.; 54 patients with benign 
lesions; and 43 patients with malignant lesions 
(Figure 1). Two more samples were taken from 
patients with diagnosed breast cancer who 
underwent mastectomy. The second sample was 
drawn one week and the third sample was drawn 
one month postoperatively. The patients with 
malignant lesions were further evaluated for their 
age, tumor size, lymph node involvement, and 
disease staging.  
 
Results 
  
The mean serum CA15-3 values are shown in 
Table 1. The mean in the normal group, in those 
Table 1. The mean ± SD of CA15-3 level in the normal controls, benign lesions, and malignant lesions 
groups. 
Postoperative CA15-3 level Group                          Age At presentation 1 week 1 month 
Tumor 
size 
Normal controls 
Mean 
N 
SD 
 18.63 
39 
7.36 
   
Benign lesions 
Mean 
N 
SD 
35.02 
51 
11.51 
12.85 
54 
6.18 
   
Malignant lesions 
Mean 
N 
SD 
45.49 
43 
11.19 
22.11 
43 
25.63 
18.3 
 
14.59 
21.75 
 
19.65 
4.32 
 
34.60 
Total Mean SD 
39.81 
12.46 
17.47 
15.87 
18.30 
14.59 
21.75 
19.65 
4.32 
4.60 
29%
39%
32% Normal
controls
Benign lesions
Malignant
lesions
Figure 1. Three groups of patients and their 
percentages analyzed for CA15-3. 
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with benign lesions, and in patients with malignant 
lesions were all below the cut-off value. 
Nonetheless, abnormal CA15-3 values are 
observed in all three groups. With one or more 
patients in each group (Figure 2), after the clinical 
staging was performed, the premastectomy CA15-
3 values were reevaluated according to the stage 
(Figure 3). It is apparent that the higher the disease 
stage, the higher is the frequency of abnormal 
CA15-3 values, when compared to those in stage I. 
The mean serum CA15-3 level slightly dropped 
one week after mastectomy. However, one month 
later, the value returned back to approximately the 
same preoperative value (Table 1).  
In patients with malignant breast lesions, the 
age ranged from 27 to 66 years (mean ± SD: 45.5 ± 
11.1). The tumor size in these patients ranged from 
one to 11 cm in diameter (mean ± SD: 4.3 ± 4.6). 
No correlation was found between CA15-3 marker 
level and the patients age or tumor size. The 
number of lymph nodes involved ranged from one 
to ten nodes. There was no significant difference in 
CA15-3 level among the studied groups when 13 
lymph nodes were involved. However, CA15-3 
values increased in most cases when ≥4 lymph 
nodes were involved (Figure 3).  
In our study, CA15-3 values, as a diagnostic 
test, had a sensitivity of 14.0% and a specificity of 
92.3%. The positive and negative predictive values 
were 66.7% and 49.3%, respectively. The relative 
efficiency was only 1.8% (Table 2). A greater 
number of patients were in the malignant group (6 
out of 43), as compared to the normal controls (3 
out of 39), and patients with benign lesions (1 out 
of 54). Patients with stages II and III disease had a 
higher likelihood for having abnormal CA15-3 
values, when compared to those with stage I 
disease.  
 
Discussion 
  
The mean serum CA15-3 values for normal 
controls, benign lesions, and patients with malig-
nant breast lesions were all below the cut-off value 
of 30 U/mL. The mean ± SD value of CA15-3 for 
those with malignant lesions (22.1 ± 25.6 U/mL) 
was higher than that for those with benign breast 
lesions and the normal controls (12.9 ± 6.2 and 
18.6 ± 7.4, respectively). No doubt, CA15-3 assay 
has no place in screening for early diagnosis of 
breast cancer. This was shown by the low 
sensitivity of the test (14.0%). The mean CA15-3 
value between benign and malignant lesions was 
significant (P < 0.05) (Table 2). 
One or more patients had elevated CA15-3 
values in all three groups. However, the frequency 
of preoperative abnormal CA15-3 values for 
patients with cancer was approximately twice that 
observed in those in normal control group. After 
clinical staging, abnormally elevated CA15-3 
levels were noted in 13.2% of stage I patients; 
whereas slightly over 40% of stages II and III 
patients had elevated levels (Figure 2). Therefore, 
CA15-3 assays could be a good marker for 
evaluating the progression of breast cancer. 
Following mastectomy, CA15-3 levels were 
evaluated two more times. The results showed a 
slight drop in the mean CA15-3 value one week 
after mastectomy, which returned back to the pre-
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Figure 2. Number of abnormal CA15-3 in 
different groups of patients. 
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Figure 3. Frequency of elevated CA15-3 values in 
different stages of breast cancer. 
Table 2. The sensitivity, specificity, positive and 
negative predictive values, and relative 
efficiency for CA15-3, as a test for early 
diagnosis of breast cancer. 
Sensitivity for CA15-3             14.0% 
Specificity for CA15-3              92.3% 
Positive predictive value 66.7% 
Negative predictive value 49.3% 
Relative efficiency 1.81% 
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operative level after one month. Since CA15-3 has 
a long half-life, a significant drop in CA15-3 
antigen may not become obvious until three 
months after removal of the bulk mass of the 
tumor.5 It is, therefore, recommended that patients 
with malignant lesions should be followed up for 
an extended period of time after mastectomy, so 
that the value of CA15-3 can be followed. 
No correlation was found between the age of 
the patients and CA15-3 values. However, in 
another study,6 a correlation was noted with the age 
of patients. In our study, there was also no correla-
tion between the tumor size and CA15-3 levels. 
There was an abnormal elevation in CA15-3 
values, when ≥ 4 lymph nodes were involved. The 
correlation between the elevated CA15-3 values 
and the number of involved lymph nodes, as 
compared with the total number of lymph nodes, 
was significant (P < 0.001). This confirms that 
CA15-3 assays are valuable in evaluating the 
progression of the disease. 
Elevated CA15-3 levels are more common in 
metastatic breast cancer patients than with other 
tumor markers (e.g., carcinoembryonic antigen 
[CEA]).7 We noted a greater frequency of 
abnormal CA15-3 values in patients with 
malignant lesions than normal controls and patients 
with benign lesions. This finding is consistent with 
other reports.8 CA15-3 has been shown to be 
elevated in 95% of cases where metastasis existed.7 
However, in our study only 4% showed an 
elevation in CA15-3. These values support the fact 
that CA15-3 is more valuable than CEA and is 
gradually replacing CEA in follow-up of patients 
with metastatic breast cancer. 
Contrary to its low sensitivity value, the 
specificity of CA15-3 is high (92.3%). The 
specificity was shown to be 100% in another 
 report.9 Considering the fact that the early 
detection of cancer recurrence is of paramount 
importance, a study for an extended period of time 
is necessary to make a definite judgment on use of 
CA15-3.10 
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